The fast and reliable anti-leishmaniasis antibody detection
method
was developed using citrate-capped gold nanoparticles (AuNPs) conjugated
with an immunogenic peptide from promastigote surface antigens. These
conjugates recognize specific antibodies that promote the aggregation
of AuNPs in the solution, enabling a remarkable surface-enhanced Raman
scattering (SERS) activity which allowed the development of an indirect
detection test for human visceral leishmaniasis (VL). Dynamic and
static light scattering methods were performed to investigate the
aggregation process of the peptide-capped AuNPs induced by the addition
of the specific polyclonal antibody anti-PSAdP23–47 in the
diagnostic test. UV–vis spectroscopy and scanning electron
microscopy demonstrated that AuNPs of different sizes are formed after
interacting with antibodies against promastigote surface antigen (PSA)-derived
peptides from the amino acid residues 23–47 (PSAdP23–47), confirmed by the plasmon resonance band position from 536 to 639
nm and light-scattering techniques. Experimental optimization of the
SERS-based serological test showed that increasing the peptide and
the citrate buffer concentration induces stronger Raman intensities.
In addition, the multivariate curve resolution with alternating least
squares allowed the identification of a fingerprint window within
the range of 1043–1498 cm–1. Finally, a refined
data analysis approach was successfully employed, enabling a robust
differentiation between human sera from VL and non-VL patients. Prototype
validation and proof of concept to demonstrate the feasibility and
functionality of the sensor were carried out through calibration and
optimization using a partial least squares discriminant analysis model
with six latent variables, which validated the test reaching 100%
sensitivity and 88.2% specificity. These results show the potential
of the SERS platform for constructing a point-of-need serological
test for diagnosing VL, a neglected tropical disease with a strong
humoral immune response.